Key clinical point: Poly (ADP-ribose) polymerase inhibitors are less cost effective than intravenous chemotherapy for ovarian cancer patients with BRCA1/2 mutations.

Major finding: Costs per quality-adjusted month of progression-free survival were $6,412 for non–platinum-based intravenous chemotherapy, $12,187 for bevacizumab-containing regimens, $16,327 for olaparib, $16,637 for rucaparib, and $18,970 for niraparib.

Study details: A modeling study comparing costs and quality-adjusted progression-free survival with different treatments for platinum-resistant ovarian cancer.

Disclosures: The authors did not report any external funding for this study. Some authors disclosed relationships with a range of pharmaceutical, device, and cancer-related businesses.